CA 102NAlternative Names: CA102N; HA-Nimesulide; Hyaluronic acid nimesulide-NH2 bioconjugate
Latest Information Update: 01 Jun 2016
At a glance
- Originator Holy Stone Healthcare
- Class Antineoplastics; Drug conjugates
- Mechanism of Action CD44 antigen inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Colorectal cancer